A Phase 4 interventional study of Gabapentin and Gabapentin in Renal Impairment, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 1 site in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Renal Insufficiency with a site in Japan — 1 open to participants now, 3 under way, 1 of them phase 3. Renal Insufficiency · Japan.
Among the 39 studies in Renal Insufficiency with a site in Japan, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2010, is one of 6 in phase 4, and was the 8th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →1 of the 39 studies in Renal Insufficiency with a site in Japan is open now. Recruiting first, the newest first:
Medtronic · Sites in Japan, United States, Argentina and 38 more countries
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 35 across the 31 interventional studies, 1,149 across the 7 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 4 studies filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
1 of the studies in Renal Insufficiency with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Renal Insufficiency with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the pharmacokinetics (PK) following administration of gabapentin in Japanese epileptic patients with renal impairment to confirm if there are any clinically relevant differences between the plasma gabapentin concentration simulated by population PK model, which was used for the evidence of the dose adjustment for the patients with renal impairment, and observed plasma gabapentin concentration.
Only one subject was able to be enrolled. Given enrollment challenges to identify additional appropriate subjects, discussion was held with the Japan Pharmaceuticals and Medical Devices Agency (PMDA) and it was agreed with the PMDA to terminate this study. The study was terminated on December 14, 2010. The study was not terminated due to any safety findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Gabapentin
Drug: Gabapentin
Drug: Gabapentin
100-200mg once a day
200-500mg once a day
400-1000mg (200-500 mg twice a day)
Observed Plasma Gabapentin Concentration
Plasma gabapentin concentrations were measured on Day 8 and Day 15
Time frame: Days 8 and 15
Ratio of Observed Plasma Gabapentin Concentration to Predicted Plasma Gabapentin Concentration Based on Population Pharmacokinetics Model
Ratio of observed plasma gabapentin concentration to predicted plasma gabapentin concentration based on population pharmacokinetics model were calculated on Day 8 and Day 15, respectively.
Time frame: Days 8 and 15
Ratio of Observed Plasma Gabapentin Concentration to Individual Predicted Plasma Gabapentin Concentration
Ratio of observed plasma gabapentin concentration to individual predicted plasma gabapentin concentration were calculated on Day 8 and Day 15, respectively.
Time frame: Days 8 and 15
Study Initiation Date and Completion Dates: 16 March 2010 to 1 April 2010 Study Center: 1 center in Japan
| Milestone | Gabapentin |
|---|---|
| Started | 1 |
| Completed | 1 |
| Not completed | 0 |
Plasma gabapentin concentrations were measured on Day 8 and Day 15
| µg/mL | Gabapentin |
|---|---|
| Day 8 | 38.40 (38.40 to 38.40) |
| Day 15 | 44.64 (44.64 to 44.64) |
Ratio of observed plasma gabapentin concentration to predicted plasma gabapentin concentration based on population pharmacokinetics model were calculated on Day 8 and Day 15, respectively.
| Ratio | Gabapentin |
|---|---|
| Day 8 | 2.16 |
| Day 15 | 2.59 |
Ratio of observed plasma gabapentin concentration to individual predicted plasma gabapentin concentration were calculated on Day 8 and Day 15, respectively.
| Ratio | Gabapentin |
|---|---|
| Day 8 | 1.15 |
| Day 15 | 1.37 |
Collected over From Day -7 (informed consent) until 28 days after the end of study treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gabapentin | — | 0/1 (0%) | 0/1 (0%) |
| Age, Customized(Participant) | Gabapentin |
|---|---|
| <=19 years | 0 |
| 20-64 years | 1 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Gabapentin |
|---|---|
| Female | 0 |
| Male | 1 |
The record gives a start of Mar 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →